1. Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
- Author
-
Brickley EB, Connor RI, Wieland-Alter W, Weiner JA, Ackerman ME, Arita M, Gast C, De Coster I, Van Damme P, Bandyopadhyay AS, and Wright PF
- Subjects
- Adolescent, Adult, Antibodies, Viral, Antibody Formation, Belgium, Feces, Humans, Middle Aged, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccines, Attenuated, Young Adult, Poliomyelitis, Poliovirus
- Abstract
In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18-50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF